Vifor Pharma adds to chronic kidney disease lineup with pair of acquisitions


Urinary system, bladder, kidney

Nephrology products company Vifor Pharma is shelling out about $252 million combined up front to acquire Sanifit Therapeutics and Inositec, developers of drugs for a blood vessel complication affecting some chronic kidney disease patients. Both biotechs are in clinical trials with their respective lead drug candidates.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.